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A B S T R A C T
Cardiac dysfunction is a common accompaniment to severe sepsis. Clinical management of the same
complicating pregnancy presents unique challenges balancing maternal and fetal well-being. Can short-
term intravenous (IV) tri-iodothyronine (T3) be used in the management of these patients? T3 has been
reported in varied clinical settings to favorably affect cardiac lusitropy, inotropy, and chronotropy
without signiﬁcant side effects.
We report a case of acute severe left ventricular dysfunction in a pregnant woman with severe acute
respiratory distress syndrome on veno-venous extracorporeal membrane oxygenation managed with
short-term IV T3. Hemodynamic stability was rapidly achieved and the improvement in contractility
imaged in real time by transesophageal echocardiography.
<Learning objective: Tri-iodothyronine (T3) rapidly affects cardiac inotropy, lusitropy, chronotropy,
and systemic vascular resistance. Widespread application of intravenous T3 for treatment of heart failure
is currently limited by a paucity of scientiﬁc literature. Selective short-term intravenous T3 use is an
underutilized adjunct in the management of acute left ventricular dysfunction.>
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Severe sepsis is characterized by an inappropriate immune
response to an infective stimulus complicated by end organ
dysfunction. Cardiac dysfunction, etiologically complex, is com-
monly encountered in the septic patient and remains an
independent marker of poor outcomes [1]. When the above
complicates pregnancy, clinical challenges balancing maternal and
fetal risks arise to optimize outcomes. Pressor uptitration increases
myocardial work while inotropic infusion in the setting of a
profound vasodilatory state might worsen hypotension. Can short-
term intravenous (IV) tri-iodothyronine (T3) be utilized for the
management of such a patient?
We report the case of a 23-week pregnant woman on veno-
venous extracorporeal membrane oxygenation (V-V ECMO) for
severe acute respiratory distress syndrome (ARDS), complicated by
acute severe left ventricular dysfunction of likely septic etiology for* Corresponding author at: 201 Lyons Avenue, Newark, NJ 07112, USA.
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1878-5409/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightswhich short-term IV T3 was used. A rapid improvement in
biventricular systolic function was noted within minutes of T3
administration. Hemodynamic stability was immediately achieved
and the improvement in contractility imaged in real time by
transesophageal echocardiography (TEE).
Case report
A 31-year-old Portuguese, 23 weeks, pregnant female pre-
sented to our hospital with severe resting dyspnea. She had
recently completed a prescription of azithromycin for an upper
respiratory infection. Upon presentation, she was febrile [Tmax
38.8 8C (102 8F)], normotensive (blood pressure 116/75 mmHg),
and tachycardic (116–120 beats/min sinus tachycardia). Peripheral
oxygen saturation on room air was 47%. An arterial blood gas test
reported pH 7.25/PaCO2 51 mmHg/PaO2 26 mmHg with a
PaO2/FIO2 ratio 51. Admission electrocardiogram reported sinus
tachycardia without signiﬁcant ST-T changes (Fig. 1A). Emergent
endotracheal intubation was undertaken. Computed tomography
scan showed diffuse bilateral ground glass consolidations and
ruled out pulmonary embolus (Fig. 1B). System review was
positive for fever, productive cough, and peripheral cyanosis. reserved.
Fig. 1.
(A) Admission electrocardiogram (ECG). (B) Computed tomography
scan demonstrating diffuse bilateral ground glass consolidation. (C)
Post-T3 ECG.
G.K. Visveswaran et al. / Journal of Cardiology Cases 13 (2016) 33–3634Admission drug screen was negative with an uneventful pregnancy
reported to date. Past history was positive for mild intermittent
asthma and an uncomplicated Cesarean section 9 years previously.
Treatment per sepsis guidelines was instituted. Hypoxia
remained refractory despite bilevel ventilation, recruitment
maneuvers, and rescue inhalational nitric oxide (NO) at 20 parts-
per-million (ppm) used to alleviate ventilation-perfusion mis-
match. Fetal health was ascertained to be normal and noncontrib-
utory to her hypoxia. Biomarker assay returned troponin I 1.08 ng/
ml (high normal <0.03 ng/ml) and B-type natriuretic peptide (BNP)
130 pg/ml (high normal <400 pg/ml) with normal serum creatinine
0.63 mg/dl (55 mmol/L). An echocardiogram revealed moderate to
severe diffuse left ventricular hypokinesis, estimated ejection
fraction 34%, and no signiﬁcant valvular pathology. The right
ventricle was mildly dilated and mildly hypokinetic. Acute
coronary ischemia, myocarditis, dilated and peripartum cardiomy-
opathy were considered, but remained lower on our differential
diagnosis. Cardiac dysfunction was attributed to the severe sepsis
and hypoxemia and labeled ‘‘septic cardiomyopathy.’’A right heart catheterization prior to ECMO revealed right atrial
pressure 10 mmHg, pulmonary artery pressure 25/15/21 mmHg,
pulmonary capillary wedge pressure 15 mmHg, and SVO2 of 73%.
V-V ECMO was initiated using a 27Fr MAQUET Avalon Elite bicaval
dual lumen catheter via the right internal jugular vein. The
ventilator was adjusted to rest settings (TV 3–4 ml/kg) and NO at
20 ppm was continued. She became acutely hypotensive post-
ECMO initiation for which vasopressin was initiated. Milrinone
was subsequently initiated for management of acute biventricular
dysfunction. To further optimize oxygen delivery and reduce
myocardial stress, she was transfused 2 units of packed red blood
cells for baseline hemoglobin of 9.6 g/dl. Empirical broad spectrum
antibiotic coverage was started with vancomycin, piperacillin-
tazobactam, azithromycin, and oseltamivir at treatment doses.
Twenty-four hours after V-V ECMO, she remained persistently
hypotensive (blood pressure 70–88/49–56 mmHg) despite inten-
sive medical management (vasopressin 0.1 units/min; milrinone
0.375 mcg/kg/min) and an arterial PaO2 130 mmHg. Vasopressin
and milrinone were changed to dobutamine and dopamine to
offset splanchnic vasoconstriction and vasodilatory effects, re-
spectively. An emergent transesophageal echocardiogram was
indicative of severe global left ventricle hypokinesis (ejection
fraction 25–30%) with mild to moderate right ventricular
hypokinesis (Figs. 2 and 3) (Videos 1 and 2). Based on favorable
reports in nongravid adults with heart failure, and, in an effort to
prevent pressor escalation, which could have compromised fetal
health, a decision was made to use IV T3 (Pregnancy Class A).
Repeat thyroid function testing was not undertaken prior to IV T3
with normal prenatal thyroid function results. A 10 mcg bolus was
administered with concurrent TEE imaging. An immediate and
remarkable improvement in biventricular systolic function was
seen (Figs. 2 and 3) (Videos 3 and 4). T3 was continued as a drip at
2.5 mcg/h, and titrated empirically to a heart rate 100 beats/min
for the next 48 h. Dopamine was discontinued within 24 h of T3
administration. Intravenous furosemide was used for diuresis and
heparin was continued per ECMO protocol.
Supplementary material related to this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.jccase.2015.09.
005.
No additional pressor or inotrope uptitration was needed.
ECMO weaning was initiated on day 4 and decannulation was
achieved on day 6. Dobutamine was discontinued 2 days later. She
was extubated on day 10 and discharged from the intensive care
unit (ICU) on day 12. Her post-ICU hospitalization was uneventful.
A viral etiology for ARDS was considered likely. An exhaustive
infectious work up returned negative, although exposure to
antibiotics prehospitalization could confound the same. Electro-
cardiogram post-T3 reported sinus rhythm without signiﬁcant ST-
T wave changes (Fig. 1C). She was discharged to home on day 20 on
metoprolol, hydralazine, and nitrates for heart failure manage-
ment. A predischarge echocardiogram showed normal biventri-
cular systolic function. This rapid normalization supports septic
cardiomyopathy as likely etiology of her cardiac dysfunction.
Obstetric ultrasound done on day 18 reported mild fetal
ventriculomegaly which was not reported on subsequent prenatal
testing post-discharge. An elective Caesarian section was under-
taken at 39 weeks for decreased fetal movements delivering a baby
girl weighing 3779 g/8 lb 5 oz. The baby had Apgar scores of 9/9.
Mother and baby were discharged home 3 days post-partum with
excellent outcomes.
Discussion
T4 and T3 are the predominant circulating thyroid hormones in
humans. T4 deiodination to biologically active T3 is catalyzed by
tissue speciﬁc Type 1 (D1) and Type 2 (D2) deiodinases. Type 3 (D3)
Fig. 2. Pre- and post-T3 transesophageal echocardiography (TEE) 4-chamber views at end diastole and end systole.
Fig. 3. Pre- and post-T3 transesophageal echocardiography (TEE) transgastric views at end diastole and end systole.
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T4 to reverse T3 (rT3). Systemic illnesses, both acute and chronic,
are associated with downregulation of D1 and D2 activities and
upregulation of D3 deiodinase activity [2], particularly illnesses
that include substantial ischemia or infarction [3]. Culminating in
low serum T3, high rT3, a low or normal T4, and normal thyroid-
stimulating hormone levels, this is commonly referred to as Non-
Thyroidal Illness Syndrome, Low T3 Syndrome (LT3S), or the Sick
Euthyroid State.
T3 has been shown to affect cardiac inotropy, lusitropy,
chronotropy, and systemic vascular resistance through a variety
of genomic and nongenomic pathways affecting ionic currents and
cardiac structural, contractile, and regulatory proteins. A decreasein systemic vascular resistance, increased left ventricular diastolic
relaxation, and systolic ventricular force generation (dp/dt)
associated with positive ventriculo-arterial coupling have been
shown with T3 administration [2,4,5]. This may explain the
decrease in aldosterone, norepinephrine, and NT-proBNP levels; a
deactivation of the neuroendocrine proﬁle was noted with T3
administration in chronic heart failure [6].
Chronic heart failure patients show biochemical evidence of
LT3S [7,8]. LT3S prevalence in these patients is positively
correlated with New York Heart Association symptom class and
disease severity [7,8]. Construed as evidence of ‘‘fetal gene
phenotype’’ reactivation minimizing energy expenditure and
protein catabolism short term, animal experiments demonstrate
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and severity has been shown to be an independent predictor of
decreased survival in heart failure patients [7,9]. Iatrogenic
supplementation to restore T3 levels to the physiologic range in
heart failure has been fraught with challenges, given lack of
sufﬁcient scientiﬁc evidence regarding dosage, timing, mode, and
duration of administration. Nonetheless, small studies have
demonstrated an improvement in mean arterial pressure, stroke
volume, and cardiac index after the administration of T3 without a
signiﬁcant increase in heart rate, occurrence of arrhythmias, or
increased myocardial oxygen demand [2,6,10]. T3 supplementa-
tion has been studied in adult [10] and pediatric open heart
surgical patients [11]. Use has extended to treatment of acute
myocardial dysfunction of donor heart allografts post-brain death
[12] and management of acute transplant allograft dysfunction.
While it is apparent that no laboratory evidence of a low T3
state was documented in our patient, a decision to use T3 was
made based on our prior heart transplant experience backed by the
available scientiﬁc evidence. Her pregnant state with a viable fetus
necessitated a novel therapeutic approach. Pressor uptitration
could have potentially compromised utero-placental circulation
and jeopardized fetal well-being. A low T3 loading and mainte-
nance dose was chosen based upon our experience in the post-
heart transplant population. Titration to physiological replacement
levels as has been done elsewhere [6] was not undertaken due to
nonavailability of free T3 laboratory testing in house.
Real time TEE imaging during T3 administration helped
document an immediate improvement in systolic function. Most
likely mediated by nongenomic actions on ion channel conduction
properties, a potentiation of the vasopressor and inotropic actions
of the other infusions was likely partially responsible. Short-term
IV T3 infusion helped achieve hemodynamic stability without
adverse effects and facilitated pressor/inotrope de-escalation,
successful ECMO decannulation, shortened ICU stay, and early
discharge home. Most importantly, she was able to maintain the
pregnancy to term with an excellent fetal and maternal outcome.
Our report highlights the safe use of IV T3 for acute ventricular
dysfunction complicating pregnancy. Concurrent TEE imaging
helped document the immediate improvement in cardiac functionthat has heretofore not been reported. Selective short-term IV T3
may therefore be an important underutilized adjunct in the
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